Introduction: The measurement of cardiospecifi c troponins is pivotal in the diagnostic and prognostic approach of patients with suspected acute myocardial infarction (AMI). However, no information is available on the commutability of results between the novel highly-sensitive (HS) troponin T (TnT) and I (TnI) immunoassays.
Introduction
The measurement of cardiospecifi c troponins is a mainstay in the diagnostic and prognostic approach of patients with suspected acute myocardial infarction (AMI). Reliable evidence has been gathered about an excellent correlation between the upper measuring range of the new, highly sensitive (HS) Troponin T (TnT) immunoassay and the values obtained for the former 4 th generation immunoassay (1) . No information has however been provided on the commutability of results between TnT and troponin I (TnI) immunoassays, to the best of our knowledge. Therefore, the aim of this study was to compare the data obtained by the Roche highly sensitive Troponin T (HS-TnT) (Roche Diagnostics GmbH, Basel, Switzerland) and the novel prototype HS-AccuTnI (Beckman Coulter Inc., Brea CA, USA) immunoassays in patients admitted at the emergency department (ED) with suspected AMI.
Materials and methods
The study population consisted in 47 consecutive patients presenting at the ED of the Academic Hospital of Parma with suspected AMI over one 
Discussion
This is the fi rst investigation assessing the correlation of HS-TnT with the novel HS-AccuTnI in patients with and without AMI, to the best of our knowledge. In the latter category of patients, this was especially allowed by the remarkably improved analytical sensitivity of these novel methods. Although our study is relatively small, the results attest that two rather diff erent biological relationships exist between TnI and TnT in plasma, depending on the source of release of these proteins from the myocardium. In the former instance, which is characterized by the physiological renewal of the cardiomyocytes or mechanical stretch of cardiomyocytes due to pressure or volume overload in subjects without AMI (5), the concentration of TnT in plasma is nearly one third of that of TnI. Conversely, after irreversible ischemic myocardial injury and necrosis, the concentration of TnI in plasma becomes nearly 10-time higher than that of TnT. It is thereby misleading to perform correlation analysis after mixing AMI cases and controls. This observation has also important clinical implications. Due to the increasing diff usion of the "hub and spoke" network model in healthcare, which is also characterized by centralization of intensive Lippi G. et al.
Commutability of results of troponin testing
therapy/intensive treatment cardiology units (6), the fi rst sample for troponin testing might be drown in a peripheral ED, from where critical patients might then be transferred to the reference hospital of the area. Since in several national settings the peripheral and the core laboratories might use diff erent troponin immunoassays (i.e., HS-TnI versus HS-TnT), our results clearly attest that the non-commutability of data jeopardizes the clinical decision making based on results of diff erent immunoassays and, even more importantly, makes it impossible to calculate the delta or reference change value between the fi rst and the following troponin results (7), and fi nally establish a reliable kinetics of troponin release from the injured myocardium.
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